A recent study calls into question the safety of mirtazapine in the elderly, an antidepressant often recommended in the elderly for treatment of senile cachexia due to the medication’s appetite stimulation properties. This episode reviews the SYMBAD trial with guest Sarah Grady, PharmD.

Guest:
Sarah Grady, PharmD
Drake University

Redeem your CPE or CME credit here!

• Pharmacist members
• CME

Need a membership?

• Join for CPE Credit
• Join for CME Credit 

References and resources: Banerjee S, High J, Stirling S, et al. Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial. Lancet. 2021 Oct 23;398(10310):1487-1497. doi: 10.1016/S0140-6736(21)01210-1. PMID: 34688369; PMCID: PMC8546216.

Continuing Education Information:
Learning Objectives: 

1. Describe the results of the SYMBAD study and its implications in the care of geriatric patients
2. Discuss the adverse effects found in the SYMBAD study 

Dr. Sarah Grady reports no actual or potential conflicts of interest associated with this episode.

0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-401-H01-P
Initial release date: 12/20/21
Expiration date: 12/20/22
Additional CPE & CME details can be found here (www.ceimpact.com/podcast)

Follow CEimpact on Social Media:
LinkedIn
Instagram